BR0111294A - Compostos com um grupo sulfonamida e composições farmacêuticas que contêm estes compostos - Google Patents

Compostos com um grupo sulfonamida e composições farmacêuticas que contêm estes compostos

Info

Publication number
BR0111294A
BR0111294A BR0111294-5A BR0111294A BR0111294A BR 0111294 A BR0111294 A BR 0111294A BR 0111294 A BR0111294 A BR 0111294A BR 0111294 A BR0111294 A BR 0111294A
Authority
BR
Brazil
Prior art keywords
compounds
group
erythrocytes
pharmaceutical compositions
compositions containing
Prior art date
Application number
BR0111294-5A
Other languages
English (en)
Inventor
Walter Elger
Alexander Hillisch
Annemarie Hedden
Sigfrid Schwarz
Klaus Schoellkopf
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7644802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0111294(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0111294A publication Critical patent/BR0111294A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSTOS COM UM GRUPO SULFONAMIDA E COMPOSIçõES FARMACêUTICAS QUE CONTêM ESTES COMPOSTOS". A invenção refere-se a compostos que agindo como uma pródroga e/ou suporte permitem que um agente ativo seja captado pelos eritrócitos e/ou um agente ativo seja ligado aos eritrócitos. A captação destes compostos pelos eritrócitos e/ou a ligação dos mesmos aos eritrócitos é tornada possível por um grupo de fórmula -SO~ 2~NR^ 1^R^ 2^, em que R^ 1^ e R^ 2^, independentemente um do outro significam um átomo de hidrogênio, um grupo acila, um grupo alquila, um grupo cicloalquila, um grupo arila, um grupo ciano ou um grupo hidróxi. As pró-drogas da invenção permitem que ingredientes ativos, como substâncias endogênicas, substâncias naturais e substâncias sintéticas com propriedades terapeuticamente úteis que possuem um alto efeito de "primeira passagem", sejam administrados oralmente, com eficácia, ou melhoram significativamente a atividade oral dos mesmos.
BR0111294-5A 2000-05-31 2001-05-08 Compostos com um grupo sulfonamida e composições farmacêuticas que contêm estes compostos BR0111294A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10027887A DE10027887A1 (de) 2000-05-31 2000-05-31 Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
PCT/EP2001/005169 WO2001091797A2 (de) 2000-05-31 2001-05-08 Verbindungen mit einer sulfonamidgruppe und diese verbindungen enthaltende pharmazeutische zusammensetzungen

Publications (1)

Publication Number Publication Date
BR0111294A true BR0111294A (pt) 2003-06-10

Family

ID=7644802

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111294-5A BR0111294A (pt) 2000-05-31 2001-05-08 Compostos com um grupo sulfonamida e composições farmacêuticas que contêm estes compostos

Country Status (29)

Country Link
US (2) US7507725B2 (pt)
EP (1) EP1294402B2 (pt)
JP (1) JP2003534386A (pt)
KR (3) KR20080038460A (pt)
CN (1) CN1441678A (pt)
AT (1) ATE315407T1 (pt)
AU (2) AU2001265933B2 (pt)
BG (1) BG107556A (pt)
BR (1) BR0111294A (pt)
CA (1) CA2410630A1 (pt)
CZ (1) CZ2003621A3 (pt)
DE (2) DE10027887A1 (pt)
DK (1) DK1294402T4 (pt)
EA (1) EA006432B1 (pt)
ES (1) ES2256256T5 (pt)
HR (1) HRP20021038B1 (pt)
HU (1) HUP0301949A3 (pt)
IL (2) IL152932A0 (pt)
ME (1) MEP14608A (pt)
MX (1) MXPA02011844A (pt)
NO (1) NO20025739D0 (pt)
NZ (1) NZ535201A (pt)
PL (1) PL206462B1 (pt)
PT (1) PT1294402E (pt)
SK (1) SK2912003A3 (pt)
UA (1) UA76953C2 (pt)
WO (1) WO2001091797A2 (pt)
YU (1) YU90102A (pt)
ZA (1) ZA200209490B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US8026229B2 (en) 2001-08-13 2011-09-27 Sterix Limited Antitumor-active 2-alkoxyestradiol sulfamates
DE102004025966A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
DE102004025985A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estriol- und Estetrol-Prodrugs
US20050277625A1 (en) * 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
DE102004025986A1 (de) * 2004-05-21 2005-12-15 Schering Ag Steroid-Prodrugs mit androgener Wirkung
US20050282793A1 (en) * 2004-05-21 2005-12-22 Ralf Wyrwa Steroid prodrugs with androgenic action
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
US20070123500A1 (en) * 2005-11-29 2007-05-31 Gerd Mueller Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
DE102005057225A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE102005057224A1 (de) 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US20070197488A1 (en) * 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
US20070135399A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Heteroaromatic sulphonamide prodrugs
DE102005057421A1 (de) * 2005-11-30 2007-05-31 Bayer Schering Pharma Ag Heteroaromatische Sulfonamid-Prodrugs
DE102005057408A1 (de) * 2005-11-30 2007-05-31 Bayer Schering Pharma Ag Sulfamoylsulfonat-Prodrugs
US20070135375A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Sulfamoyl sulfonate prodrugs
ES2586053T3 (es) 2008-05-20 2016-10-11 Grinon Industries Conjunto de transferencia de fluidos y métodos de transferencia de fluidos
US9284174B2 (en) * 2008-05-20 2016-03-15 Grinon Industries Fluid transfer assembly and methods of fluid transfer
US8777182B2 (en) 2008-05-20 2014-07-15 Grinon Industries Fluid transfer assembly and methods of fluid transfer
US9100458B2 (en) * 2008-09-11 2015-08-04 At&T Intellectual Property I, L.P. Apparatus and method for delivering media content
CN101987102A (zh) * 2009-08-05 2011-03-23 天津金耀集团有限公司 一种糖皮质激素杂芳香基氨磺酰基羧酸酯的眼用抗炎组合物
CN101987104A (zh) * 2009-08-05 2011-03-23 天津金耀集团有限公司 一种杂芳香基氨磺酰基羧酸酯碳酸酐酶抑制剂的眼用组合物
EP3019172B1 (en) * 2013-07-11 2019-09-25 Evestra, Inc. Pro-drug forming compounds
CN108601901B (zh) 2015-11-27 2021-02-26 赛诺菲-安万特德国有限公司 具有帽的药物输送装置
EP3173113A1 (en) * 2015-11-27 2017-05-31 Sanofi-Aventis Deutschland GmbH An injection needle assembly
BR112020007673A2 (pt) 2017-10-19 2020-10-13 Evestra, Inc. contraceptivos pró-fármaco de progestina de ação prolongada

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1203042B (de) * 1963-11-21 1965-10-14 Schering Ag Fungizide Mittel
GB1593609A (en) 1978-01-31 1981-07-22 Christiaens Sa A Pyridine sulfonamides
US4244940A (en) * 1978-09-05 1981-01-13 Bio-Rad Laboratories, Inc. Single-incubation two-site immunoassay
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5001234A (en) † 1987-04-16 1991-03-19 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US4792569A (en) * 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
US5116828A (en) 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5025031A (en) * 1989-11-30 1991-06-18 A. H. Robins Co., Inc. Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants
GB9118478D0 (en) * 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
IL109431A (en) 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
DE4447715C2 (de) 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Behandlung von Prostatakarzinomen
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US5571933A (en) 1994-11-17 1996-11-05 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use
US5705495A (en) * 1995-10-19 1998-01-06 Jenapharm Gmbh & Co. Kg. Sulfamate derivatives of 1,3,5(10)-estratriene derivatives, methods for their production and pharmaceuticals containing these compounds
DE19540233B4 (de) * 1995-10-19 2005-08-25 Schering Ag Sulfamat-Derivate von 1,3,5(10)-Estratrien-Derivaten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE19712488A1 (de) 1997-03-25 1998-10-01 Knoell Hans Forschung Ev Steroidsulfamate, Verfahren zu ihrer Herstellung und Anwendung derselben
DE19723794A1 (de) * 1997-06-06 1998-12-10 Jenapharm Gmbh Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
EP1100736A1 (en) 1998-07-29 2001-05-23 Crisplant A/S Parcel singulation system
US6583130B1 (en) 1999-09-13 2003-06-24 Schering Ag C13-substituted estra-1,3,5,(10)-trien-3-yl sulfamates, methods of preparing same, and pharmaceutical compositions containing these compounds
US6958327B1 (en) * 1999-11-02 2005-10-25 Schering, Ag 18 Norsteroids as selectively active estrogens
BR0107630A (pt) * 2000-01-14 2002-10-08 Schering Ag Composição
PL207488B1 (pl) 2000-04-12 2010-12-31 Schering Ag Pochodne estra-1,3,5(10)-trienu podstawione w pozycji 8ß, ich zastosowanie oraz kompozycja farmaceutyczna je zawierająca
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
WO2002079146A2 (en) 2001-03-02 2002-10-10 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US20020156068A1 (en) * 2001-03-22 2002-10-24 Behan Dominic P. Anti-psychosis combination
US6956031B2 (en) 2002-03-27 2005-10-18 Schering Aktiengesellschaft 11β-Substituted 19-nor-17-α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring
DE10226326A1 (de) 2002-06-11 2004-01-15 Schering Ag 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
US7414043B2 (en) 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
ATE395919T1 (de) 2003-11-26 2008-06-15 Bayer Schering Pharma Ag Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen
DE102004025966A1 (de) 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
DE102004025986A1 (de) 2004-05-21 2005-12-15 Schering Ag Steroid-Prodrugs mit androgener Wirkung
US20050277625A1 (en) 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
DE102004025985A1 (de) 2004-05-21 2005-12-15 Schering Ag Estriol- und Estetrol-Prodrugs
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450

Also Published As

Publication number Publication date
UA76953C2 (en) 2006-10-16
EP1294402B1 (de) 2006-01-11
SK2912003A3 (en) 2003-09-11
NZ535201A (en) 2007-01-26
ZA200209490B (en) 2005-03-10
US20090023896A1 (en) 2009-01-22
ES2256256T3 (es) 2006-07-16
US20040014781A1 (en) 2004-01-22
NO20025739L (no) 2002-11-29
IL152932A0 (en) 2003-06-24
WO2001091797A3 (de) 2002-06-20
DE10027887A1 (de) 2001-12-13
US7507725B2 (en) 2009-03-24
CN1441678A (zh) 2003-09-10
HUP0301949A3 (en) 2010-01-28
HUP0301949A2 (hu) 2003-09-29
DK1294402T3 (da) 2006-05-22
IL152932A (en) 2007-07-04
CA2410630A1 (en) 2002-11-28
HRP20021038A2 (en) 2004-10-31
DE50108674D1 (de) 2006-04-06
EA200201201A1 (ru) 2003-06-26
CZ2003621A3 (cs) 2003-12-17
PT1294402E (pt) 2006-05-31
NO20025739D0 (no) 2002-11-29
WO2001091797A2 (de) 2001-12-06
EA006432B1 (ru) 2005-12-29
JP2003534386A (ja) 2003-11-18
ES2256256T5 (es) 2009-12-11
DK1294402T4 (da) 2009-11-23
KR20080038460A (ko) 2008-05-06
BG107556A (bg) 2004-01-30
EP1294402B2 (de) 2009-08-12
YU90102A (sh) 2006-05-25
MEP14608A (en) 2010-06-10
PL361426A1 (en) 2004-10-04
PL206462B1 (pl) 2010-08-31
KR20030017524A (ko) 2003-03-03
AU6593301A (en) 2001-12-11
HRP20021038B1 (en) 2008-08-31
AU2001265933B2 (en) 2007-10-18
MXPA02011844A (es) 2004-05-17
KR20090090398A (ko) 2009-08-25
ATE315407T1 (de) 2006-02-15
EP1294402A2 (de) 2003-03-26

Similar Documents

Publication Publication Date Title
BR0111294A (pt) Compostos com um grupo sulfonamida e composições farmacêuticas que contêm estes compostos
BR9714634A (pt) Carbamatos de benzimidazola-2 para o tratamento de infecções viróticas de câncer
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
NO317153B1 (no) Anvendelse av flavanolignaner for fremstilling av medikamenter med antiproliferativ aktivitet i uterus, ovarium og bryst
BRPI0508263A (pt) derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
BR9811818A (pt) Uso de um composto, composto, e, composição farmacêutica
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
DK1157037T3 (da) GCSF-konjugater
BRPI0518068A (pt) composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada
BR9912073A (pt) Composições farmacêuticas que compreendem 2-quinolonas
EA200701239A1 (ru) 18-метил-9-нор-17-прегн-4-ен-21,17-карболактоны, а также лекарственные препараты, которые их содержат
BRPI0414864A (pt) composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida
HUT75513A (en) Taxane class derivative based pharmaceutical compositions and their preparation
BRPI0408477A (pt) compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR0008297A (pt) Uso de 4,6-o-(benzilideno-d1) -d-glucopiranose, 4,6-o-benzilideno-l-glucopiranose, e/ou 4,6-o-(benzilideno-d1) -l-glucopiranose, ou um sal farmacêutico aceitável dos mesmos, derivado de benzaldeìdo composição farmacêutica, e, processo para a fabricação da mesma
BRPI0518560A2 (pt) composto antitrombàtico, composiÇço farmacÊutica, processo para a preparaÇço do composto e uso do composto
BRPI0410623A (pt) composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
DK1140115T3 (da) Phospholipidkomplekser af proanthocyanidin A2 som antiatherosclerotiske midler
PT981358E (pt) Derivados de dolastatina-15 em combinacao com taxanos
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
BR9912817A (pt) Composição terapêutica à base de isoflavonóides destinada a ser utilizada no tratamento dos tumores por agentes citotóxicos
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение
BR0209796A (pt) Moduladores de receptor ampa alostérico naftotiazina positivos (paarm)

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.